ERIC REYNOLDS: Open Payments
NPI 1710311279 · VERNAL, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$560 in 25 payments from 9 companies in 2025. Trend: 2023 $641 · 2024 $603 · 2025 $560
Food & beverage: $560
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $239 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $109 |
| Lundbeck LLC | 2 | $46 |
| Novo Nordisk Inc | 2 | $41 |
| Gilead Sciences, Inc. | 1 | $31 |
| ABBVIE INC. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $23 |
| Verona Pharma, Inc. | 1 | $21 |
Products named: CAPLYTA, FARXIGA, BREZTRI, AIRSUPRA, REXULTI, Wegovy, VRAYLAR, Sunosi.
Industry payments across UT — which companies pay providers there.
